Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CSNK1A1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CSNK1A1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CSNK1A1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CSNK1A1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CSNK1A1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CSNK1A1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CSNK1A1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CSNK1A1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CSNK1A1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CSNK1A1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CSNK1A1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CSNK1A1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003243419 | Prostate | Tumor | regulation of proteasomal ubiquitin-dependent protein catabolic process | 55/3246 | 134/18723 | 8.40e-11 | 5.27e-09 | 55 |
GO:001605514 | Prostate | Tumor | Wnt signaling pathway | 131/3246 | 444/18723 | 1.16e-10 | 7.11e-09 | 131 |
GO:019873814 | Prostate | Tumor | cell-cell signaling by wnt | 131/3246 | 446/18723 | 1.61e-10 | 9.69e-09 | 131 |
GO:003011114 | Prostate | Tumor | regulation of Wnt signaling pathway | 99/3246 | 328/18723 | 5.92e-09 | 2.34e-07 | 99 |
GO:190336419 | Prostate | Tumor | positive regulation of cellular protein catabolic process | 56/3246 | 155/18723 | 1.51e-08 | 5.43e-07 | 56 |
GO:006082814 | Prostate | Tumor | regulation of canonical Wnt signaling pathway | 79/3246 | 253/18723 | 4.01e-08 | 1.25e-06 | 79 |
GO:200006019 | Prostate | Tumor | positive regulation of ubiquitin-dependent protein catabolic process | 41/3246 | 107/18723 | 1.99e-07 | 4.86e-06 | 41 |
GO:003243618 | Prostate | Tumor | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 36/3246 | 90/18723 | 3.15e-07 | 7.14e-06 | 36 |
GO:190305216 | Prostate | Tumor | positive regulation of proteolysis involved in cellular protein catabolic process | 47/3246 | 133/18723 | 4.46e-07 | 9.77e-06 | 47 |
GO:190180017 | Prostate | Tumor | positive regulation of proteasomal protein catabolic process | 42/3246 | 114/18723 | 4.99e-07 | 1.08e-05 | 42 |
GO:006007014 | Prostate | Tumor | canonical Wnt signaling pathway | 87/3246 | 303/18723 | 5.49e-07 | 1.17e-05 | 87 |
GO:001810513 | Prostate | Tumor | peptidyl-serine phosphorylation | 78/3246 | 315/18723 | 4.95e-04 | 3.66e-03 | 78 |
GO:003017813 | Prostate | Tumor | negative regulation of Wnt signaling pathway | 46/3246 | 170/18723 | 9.84e-04 | 6.37e-03 | 46 |
GO:001820913 | Prostate | Tumor | peptidyl-serine modification | 81/3246 | 338/18723 | 1.11e-03 | 7.14e-03 | 81 |
GO:009009012 | Prostate | Tumor | negative regulation of canonical Wnt signaling pathway | 38/3246 | 137/18723 | 1.60e-03 | 9.71e-03 | 38 |
GO:000703013 | Prostate | Tumor | Golgi organization | 40/3246 | 157/18723 | 6.33e-03 | 2.90e-02 | 40 |
GO:004217628 | Skin | AK | regulation of protein catabolic process | 101/1910 | 391/18723 | 4.78e-19 | 9.43e-16 | 101 |
GO:190336228 | Skin | AK | regulation of cellular protein catabolic process | 72/1910 | 255/18723 | 3.99e-16 | 1.97e-13 | 72 |
GO:001605518 | Skin | AK | Wnt signaling pathway | 98/1910 | 444/18723 | 9.39e-14 | 3.09e-11 | 98 |
GO:019873818 | Skin | AK | cell-cell signaling by wnt | 98/1910 | 446/18723 | 1.26e-13 | 3.72e-11 | 98 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSNK1A1 | SNV | Missense_Mutation | | c.178N>A | p.Glu60Lys | p.E60K | P48729 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.956) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CSNK1A1 | insertion | Nonsense_Mutation | novel | c.33_34insCTTGTTAAACACGTCCCATAAATGTCCCTTAGTCGAG | p.Ile12LeufsTer7 | p.I12Lfs*7 | P48729 | protein_coding | | | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | insertion | In_Frame_Ins | novel | c.576_577insCCA | p.Tyr192_Arg193insPro | p.Y192_R193insP | P48729 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CSNK1A1 | deletion | Frame_Shift_Del | novel | c.166delN | p.Gln56SerfsTer33 | p.Q56Sfs*33 | P48729 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
CSNK1A1 | SNV | Missense_Mutation | | c.62G>T | p.Arg21Leu | p.R21L | P48729 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.91) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
CSNK1A1 | SNV | Missense_Mutation | | c.929G>A | p.Arg310His | p.R310H | P48729 | protein_coding | deleterious_low_confidence(0) | benign(0.062) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | SNV | Missense_Mutation | rs865943998 | c.854C>T | p.Ala285Val | p.A285V | P48729 | protein_coding | tolerated_low_confidence(0.13) | benign(0.261) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | SNV | Missense_Mutation | novel | c.812N>T | p.Thr271Met | p.T271M | P48729 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.493) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | SNV | Missense_Mutation | | c.292N>A | p.Glu98Lys | p.E98K | P48729 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.975) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | SNV | Missense_Mutation | novel | c.874N>T | p.Arg292Cys | p.R292C | P48729 | protein_coding | deleterious_low_confidence(0) | benign(0.062) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SP-600125 | SP-600125 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102608 | IC261 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | AZD-1775 | ADAVOSERTIB | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | DNDI1417467 | CHEMBL1997335 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SB-220025 | SB-220025 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102563 | | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | 681640 | CHEMBL379975 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | AG-1879 | CHEMBL406845 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | PHA-767491 | CHEMBL225519 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | TAK-715 | TAK-715 | |